The impact of ω-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open-label pilot study
Abstract
Classical antipsychotics like haloperidol are suggested to increase oxidative stress and oxidative cell injury in the brain. Pro-oxidant effect of haloperidol may influence the course and treatment outcomes of schizophrenia. Dietary supplementation of either antioxidants or omega-3 fatty acids was found to improve symptoms of schizophrenia. Thus we decided to assess the impact of combining omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol. Ongoing haloperidol treatment of 17 schizophrenia patients was supplemented with 1000 mg capsule of omega-3 fatty acids (180 mg EPA+120 mg DHA) bid, vitamin E 400 IU bid and vitamin C 1000 mg/day. Patients were assessed with Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative Symptoms (SANS), Simpson Angus Scale (SAS) and Barnes Akathisia Rating Scale (BARS) over a 4 month period. Gluthatione peroxidase, superoxide dismutase, malondialdehyde, vitamin E and C levels were also evaluated at baseline and at the end of study. BPRS, SANS, SAS and BARS scores obtained at follow-up visits were significantly lower compared to baseline. Superoxide dismutase level was significantly lower at the end of study. No significant differences were detected in other laboratory parameters. Our results support the beneficial effect of the supplementation on positive and negative symptoms of schizophrenia as well as the severity of side effects induced by haloperidol. The effect of supplementation on akathisia is especially noteworthy and it has not been investigated in previous studies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Supplementation of patients with schizophrenia with vitamins C and E and omega-3 fatty acids provided positive results in terms of extrapyramidal side effects.
“Other studies reported that supplementation of patients with schizophrenia with vitamins C and E and omega-3 fatty acids provided positive results in terms of extrapyramidal side effects (Sivrioglu et al. 2007).”
From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as Sivrioglu et al. 2007
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,767 · see citing works
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · see citing works
[1] Role of free radicals and catalytic metal ions in human disease: An overview
Halliwell, B., & Gutteridge, J. M. C. (1990) · Methods in Enzymology · doi:10.1016/0076-6879(90)86093-b · Cited by 4,994 · see citing works
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265 · see citing works
Tietz Textbook of Clinical Chemistry
(1999) · Archives of Pathology & Laboratory Medicine · doi:10.5858/123.7.646b · Cited by 2,518 · see citing works
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,350 · see citing works
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179 · see citing works
Tietz Textbook of Clinical Chemistry
David (1994) · JAMA · doi:10.1001/jama.1994.03520080086056 · Cited by 707 · see citing works
Free radical pathology and antioxidant defense in schizophrenia: a review
Mahadik, S. P., & Mukherjee, S. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(95)00049-6 · Cited by 330 · see citing works
Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00083-9 · Cited by 329 · see citing works
Peet, M., & Horrobin, D. F. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00048-6 · Cited by 329 · see citing works
Fenton, W. S., Dickerson, F., Boronow, J. J., Hibbeln, J. R., & Knable, M. B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2071 · Cited by 322 · see citing works
Emsley, R. A., Myburgh, C., Oosthuizen, P. P., & van Rensburg, S. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1596 · Cited by 306 · see citing works
Methods for Assessing Positive and Negative Symptoms1
Andreasen, N. C. (2015) · Modern problems of pharmacopsychiatry/Modern trends in pharmacopsychiatry · doi:10.1159/000418013 · Cited by 282 · see citing works
Arvindakshan, M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00284-0 · Cited by 281 · see citing works
The Susceptibility to Autoxidation of Human Red Cell Lipids in Health and Disease
Stocks, J., Offerman, E. L., Modell, C. B., & Dormandy, T. L. (1972) · British Journal of Haematology · doi:10.1111/j.1365-2141.1972.tb03486.x · Cited by 245 · see citing works
Mahadik, S. P., Evans, D. R., & Lal, H. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00181-0 · Cited by 229 · see citing works
Parikh, V., Khan, M. M., & Mahadik, S. P. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00048-1 · Cited by 224 · see citing works
Free radical pathology in schizophrenia: a review
Reddy, R. D., & YAO, J. K. (1996) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(96)90143-x · Cited by 201 · see citing works
Assies, J., Lieverse, R., Vreken, P., WANDERS, R. J. A., Dingemans, P. M. A. J., & Linszen, D. H. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00986-0 · Cited by 188 · see citing works
Peet, M., Laugharne, J. D. E., Mellor, J. E., & Ramchand, C. N. (1996) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(96)90148-9 · Cited by 170 · see citing works
Enzymes of the antioxidant defense system in chronic schizophrenic patients
Reddy, R. D., Mahadik, S. P., Mukherjee, S., & Murthy, J. N. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90298-z · Cited by 156 · see citing works
Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats
Subramanyam, B., Rollema, H., Woolf, T. F., & Castagnoli, N. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91936-m · Cited by 131 · see citing works
Qing, H., Xu, H., Wei, Z., Gibson, K., & Li, X. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02590.x · Cited by 129 · see citing works
Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs
Jeding, I. B., Evans, P., Akanmu, D., Dexter, D. T., Spencer, J. D., Aruoma, O. I., Jenner, P. G., & Halliwell, B. B. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00424-k · Cited by 104 · see citing works
Mahadik, S. P., Pillai, A., Joshi, S., & Foster, A. E. (2006) · International Review of Psychiatry · doi:10.1080/09540260600581993 · Cited by 98 · see citing works
Haloperidol-induced cell death—mechanism and protection with vitamin E in vitro
Behl, C., Rupprecht, R., Skutella, T., & Holsboer, F. (1995) · Neuroreport · doi:10.1097/00001756-199512000-00085 · Cited by 88 · see citing works
Haloperidol‐Induced Neuronal Apoptosis
Noh, J. S., Kang, H. J., Kim, E. Y., Sohn, S., Chung, Y. K., Kim, S. U., & Gwag, B. J. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752327.x · Cited by 61 · see citing works
Özyurt, B., Sarsılmaz, M., Akpolat, N., Özyurt, H., Akyol, Ö., Herken, H., & Kuş, İ. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.08.002 · Cited by 60 · see citing works
Oxidative stress-resistant cells are protected against haloperidol toxicity
Behl, C., Lezoualc’h, F., Widmann, M., Rupprecht, R., & Holsboer, F. (1996) · Brain Research · doi:10.1016/0006-8993(96)00126-6 · Cited by 43 · see citing works
Rapid quantification of alpha-tocopherol in plasma and low- and high-density lipoproteins
Morier-teissier, E., Walters-Laporte, E., Duhem, C., Luc, G., Fruchart, J., & Duriez, P. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.3.430 · Cited by 42 · see citing works
Dorfman-Etrog, P., Hermesh, H., Prilipko, L. L., Weizman, A., & Munitz, H. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00015-2 · Cited by 27 · see citing works
Reddy, R. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90789-3 · Cited by 6 · see citing works
Flagged first, then by citations
3 of the 37 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638 · see citing works
Health effects of quercetin: From antioxidant to nutraceutical
Boots, A. W., Haenen, G. R. M. M., & Bast, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.008 · Cited by 2,121 · see citing works
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069 · see citing works
Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View
Yao, J. K., & Keshavan, M. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3603 · Cited by 285 · see citing works
Oxidative Stress in Schizophrenia
Grabnar, I., Vovk, T., Plesničar, B. K., & Boskovic, M. (2011) · Current Neuropharmacology · doi:10.2174/157015911795596595 · Cited by 250 · see citing works
Does Vitamin C Influence Neurodegenerative Diseases and Psychiatric Disorders?
Kocot, J., Luchowska-Kocot, D., Kiełczykowska, M., Musik, I., & Kurzepa, J. (2017) · Nutrients · doi:10.3390/nu9070659 · Cited by 245 · see citing works
Oxidative Stress‐Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives
Ermakov, E. A., Dmitrieva, E. M., Parshukova, D. A., Kazantseva, D. V., Vasilieva, A. R., & Smirnova, L. P. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8881770 · Cited by 252 · see citing works
Marsanasco, M., Márquez, A. L., Wagner, J. R., Alonso, S. D. V., & Chiaramoni, N. S. (2011) · Food Research International · doi:10.1016/j.foodres.2011.07.025 · Cited by 227 · see citing works
Implications for reactive oxygen species in schizophrenia pathogenesis
Koga, M., Serritella, A. V., Sawa, A., & Sedlak, T. W. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.06.022 · Cited by 159 · see citing works
Davis, J., Moylan, S., Harvey, B. H., Maes, M. H. J., & Berk, M. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414533012 · Cited by 147 · see citing works
The progress and application of vitamin E encapsulation – A review
Ribeiro, A. M., Estevinho, B. N., & Rocha, F. A. (2021) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2021.106998 · Cited by 106 · see citing works
Firth, J., Stubbs, B., Sarris, J. J., Rosenbaum, S., Teasdale, S. B., Berk, M., & Yung, A. R. (2017) · Psychological Medicine · doi:10.1017/s0033291717000022 · Cited by 98 · see citing works
Otte, D.-M., Sommersberg, B., Kudin, A., Guerrero, C., Albayram, Ö., Filiou, M. D., Frisch, P., Yilmaz, Ö., Drews, E., Turck, C. W., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.109 · Cited by 97 · see citing works
A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia
Bentsen, H., Osnes, K., Refsum, H., Solberg, D. K., & Bøhmer, T. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.110 · Cited by 97 · see citing works
Fond, G. B., d’Albis, M.-A., Jamain, S., Tamouza, R., Arango, C., Fleischhacker, W. W., Glenthoj, B. Y., Leweke, F. M., Lewis, S. W., McGuire, P. K., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv002 · Cited by 96 · see citing works
Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms
Hsu, M., Huang, Y. S., & Ouyang, W. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01337-0 · Cited by 88 · see citing works
Mitra, S., Natarajan, R., Ziedonis, D. M., & Fan, X. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.005 · Cited by 85 · see citing works
Polymeropoulos, M. H., Licamele, L., Volpi, S., Mack, K., Mitkus, S. N., Carstea, E. D., Getoor, L. C., Thompson, A. D., & Lavedan, C. N. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.025 · Cited by 83 · see citing works
Magnetic Resonance Spectroscopy Study of the Antioxidant Defense System in Schizophrenia
Matsuzawa, D., & Hashimoto, K. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3453 · Cited by 79 · see citing works
Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia
Zugno, A. I., Chipindo, H. L., Volpato, A. M., Budni, J., Steckert, A. V., de Oliveira, M. B., Heylmann, A. S., Silveira, F. D. R., Mastella, G. A., Maravai, S. G., et al. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.11.049 · Cited by 74 · see citing works
Patel, S., Sharma, D., Kalia, K., & Tiwari, V. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.08.025 · Cited by 64 · see citing works
A Defect in the Antioxidant Defense System in Schizophrenia
Vırıt, O., Altındağ, A., Yumru, M., Dalkiliç, A., SAVAS, H. A., Selek, Ş., Erel, Ö., & Herken, H. (2009) · Neuropsychobiology · doi:10.1159/000239684 · Cited by 63 · see citing works
Onaolapo, O. J., & Onaolapo, A. Y. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i28.8295 · Cited by 54 · see citing works
Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia
Madireddy, S., & Madireddy, S. (2020) · Brain Sciences · doi:10.3390/brainsci10100742 · Cited by 55 · see citing works
Marsanasco, M., Márquez, A. L., Wagner, J. R., Chiaramoni, N. S., & Alonso, S. D. V. (2015) · Journal of Food Engineering · doi:10.1016/j.jfoodeng.2015.05.007 · Cited by 51 · see citing works
Role of Oxidative Stress and Ca2+ Signaling in Psychiatric Disorders
Nakao, A., Matsunaga, Y., Hayashida, K., & Takahashi, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.615569 · Cited by 49 · see citing works
Pawełczyk, T., Grancow-Grabka, M., Kotlicka‐Antczak, M., Trafalska, E., Gębski, P., Szemraj, J., Żurner, N., & Pawełczyk, A. M. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0473-2 · Cited by 45 · see citing works
Albayrak, Y., Ünsal, C., Beyazyüz, M., Ünal, A., & Kuloğlu, M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.020 · Cited by 41 · see citing works
Antioxidant Therapeutics for Schizophrenia
Reddy, R. D., & Reddy, R. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3571 · Cited by 40 · see citing works
Finkelstein, J. M., Heemels, M.-T., Shadan, S., & Weiss, U. K. (2014) · Nature · doi:10.1038/510047a · Cited by 40 · see citing works
Effects of Omega-3 in the treatment of violent schizophrenia patients
Qiao, Y., Mei, Y., Han, H., Liu, F., Yang, X. M., Shao, Y., Xie, B., & Long, B. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.08.026 · Cited by 39 · see citing works
Sershen, H. W., Hashim, A., Dunlop, D. S., Suckow, R. F., Cooper, T. B., & Javitt, D. C. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1838-8 · Cited by 38 · see citing works
Pawełczyk, T., Grancow-Grabka, M., Trafalska, E., Szemraj, J., & Pawełczyk, A. M. (2017) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2017.05.004 · Cited by 35 · see citing works
Young, J., Wahle, K. W. J., & Boyle, S. P. (2007) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2007.10.005 · Cited by 35 · see citing works
Polyunsaturated fatty acids in emerging psychosis: a safer alternative?
Schlögelhofer, M., Amminger, G. P., Schaefer, M. R., Fusar‐Poli, P., Smesny, S., McGorry, P. D., Berger, G. E., & Mossaheb, N. (2014) · Early Intervention in Psychiatry · doi:10.1111/eip.12151 · Cited by 34 · see citing works
Drug repurposing and emerging adjunctive treatments for schizophrenia
Bumb, J. M., Enning, F., & Leweke, F. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032248 · Cited by 34 · see citing works
Anti-Inflammatory Diets and Schizophrenia
Yun, H. S., & Yang, S. J. (2020) · Clinical Nutrition Research · doi:10.7762/cnr.2020.9.4.241 · Cited by 33 · see citing works
Shinoda, Y., Tagashira, H., Bhuiyan, M. S., Hasegawa, H., Kanai, H., & Fukunaga, K. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.05.012 · Cited by 32 · see citing works
Michel, T. M., Sheldrick, A. J., Camara, S., Grünblatt, E., Schneider, F. W., & Riederer, P. F. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.526146 · Cited by 30 · see citing works
Altınkılıç, S., Nazıroğlu, M., Uğuz, A. C., & Özçankaya, R. (2010) · The Journal of Membrane Biology · doi:10.1007/s00232-010-9267-0 · Cited by 29 · see citing works
Frajerman, A., Scoriels, L., Kébir, O., & Chaumette, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136881 · Cited by 29 · see citing works
Oruch, R., Lund, A., Pryme, I. F., & Holmsen, H. (2010) · Journal of Chemical Biology · doi:10.1007/s12154-009-0034-6 · Cited by 26 · see citing works
Stress, psychiatric disorders, molecular targets, and more
Atrooz, F., Liu, H., & Salim, S. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.006 · Cited by 27 · see citing works
Mitochondrial Dysfunction and Oxidative Stress
Kato, T., Kapczinski, F. P., & Berk, M. (2010) · Wiley eBooks · doi:10.1002/9780470661277.ch18 · Cited by 24 · see citing works
Casquero‐Veiga, M., Romero‐Miguel, D., MacDowell, K. S., Torres-Sánchez, S., Garcia-Partida, J. A., Lamanna‐Rama, N., Gómez‐Rangel, V., Romero‐Miranda, A., Berrocoso, E., Leza, J. C., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.001 · Cited by 22 · see citing works
Sulforaphane protects SK‐N‐SH cells against antipsychotic‐induced oxidative stress
Mas, S., Gassó, P., Trias, G., Bernardo, M., & Lafuente, A. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00988.x · Cited by 22 · see citing works
Tong, J., Satyanarayanan, S. K., & Su, H. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.08.027 · Cited by 24 · see citing works
Das, U. N., & Puskás, L. G. (2009) · Lipids in Health and Disease · doi:10.1186/1476-511x-8-61 · Cited by 22 · see citing works
Nagano, T., Mizuno, M., Morita, K., & Nawa, H. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_399 · Cited by 21 · see citing works
Drews, E., Otte, D.-M., & Zimmer, A. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.10.009 · Cited by 21 · see citing works
van Rensburg, S. J., Smuts, C. M., Hon, D., Kidd, M., der Merwe, V., Myburgh, C., Oosthuizen, P. P., & Emsley, R. A. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-009-9160-7 · Cited by 21 · see citing works
Zhao, H., Han, X., Zhang, X., Li, L., Li, Y., Wang, W., McIntyre, R. S., Teopiz, K. M., Guo, L., & Lu, C. (2023) · Antioxidants · doi:10.3390/antiox12010162 · Cited by 21 · see citing works
Seafood Types and Age-Related Cognitive Decline in the Women’s Health Study
Kim, D. H., Grodstein, F., ROSNER, B. A., Kang, J. H., Cook, N. R., Manson, J. E., Buring, J. E., Willett, W. C., & Okereke, O. I. (2013) · The Journals of Gerontology Series A · doi:10.1093/gerona/glt037 · Cited by 19 · see citing works
Beeraka, N. M., Ávila-Rodriguez, M., & Aliev, G. M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02703-4 · Cited by 18 · see citing works
Damázio, L. S., Silveira, F. D. R., Canever, L., de Castro, A. A., Estrela, J. M., Budni, J., & Zugno, A. I. (2017) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201720160490 · Cited by 17 · see citing works
α-Lipoic Acid as Adjunctive Treatment for Schizophrenia
de Lima, D. N., Filho, C. W. L. C., Frota, I. J., de Oliveira, A. L. B., Menezes, C. E. D. S., Filho, A. J. M. C., Viana, G. D. A., Campos, E. D. M., Collares, M., de Queiroz, M. G. R., et al. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001639 · Cited by 16 · see citing works
Polypharmazie in der Behandlung der Schizophrenie
Messer, T., Tiltscher, C., & Schmauß, M. (2009) · Springer eBooks · doi:10.1007/978-3-211-79826-3_2 · Cited by 15 · see citing works
Chia, S. C., Henry, C. J., Mok, Y. M., Honer, W. G., & Sim, K. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1451-z · Cited by 13 · see citing works
Role of antioxidants in the neurobiology of drug addiction: An update
Kamiński, P., Lorek, M., Baszyński, J., Tadrowski, T., Gorzelańczyk, E. J., Feit, J., Tkaczenko, H., Owoc, J., Woźniak, A., & Kurhaluk, N. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116604 · Cited by 12 · see citing works
Hsu, M., & Ouyang, W. (2021) · Biological Research For Nursing · doi:10.1177/10998004211020121 · Cited by 9 · see citing works
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 8 · see citing works
A Brief Overview of Iatrogenic Akathisia
Advokat, C. D. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.3.4.5 · Cited by 7 · see citing works
Oliveira, G. L. D. S., de Oliveira, F. R. D. A. M., & de Freitas, R. M. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · doi:10.5897/ajpp2013.3963 · Cited by 6 · see citing works
Increased PLA2 activity in individuals at ultra-high risk for psychosis
Talib, L. L., Costa, A. C., Joaquim, H. P. G., Pereira, C. A. C., van de Bilt, M. T., Loch, A. A., & Gattaz, W. F. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01246-y · Cited by 6 · see citing works
Marsanasco, M., Chiaramoni, N. S., & Alonso, S. D. V. (2017) · InTech eBooks · doi:10.5772/intechopen.69117 · Cited by 6 · see citing works
Ashique, S., Paul, D., Debnath, B., Chellappan, D. K., Das, J., Bhui, U., Ramzan, M., Sharma, N., Kumar, B., Sridhar, S. B., et al. (2025) · Nutritional Neuroscience · doi:10.1080/1028415x.2025.2560658 · Cited by 5 · see citing works
Esfandiari, M., Bagheri, H., Mirarab-Razi, V., Razi, S. M., & Rashidinejad, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-28109-9_24 · Cited by 5 · see citing works
Madireddy, S., & Madireddy, S. (2022) · Journal of Neuroscience and Neurological Disorders · doi:10.29328/journal.jnnd.1001070 · Cited by 5 · see citing works
An, H. M., Tan, Y. L., Shi, J., Wang, Z. R., Li, J., Wang, Y. C., Lv, M. H., Zhou, D. F., Soares, J. C., Kosten, T. R., et al. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.10.004 · Cited by 5 · see citing works
Bartholomeusz, C. F., Killackey, E. J., Thompson, A. D., & Wood, S. J. (2011) · Springer eBooks · doi:10.1007/978-94-007-0834-1_9 · Cited by 4 · see citing works
Oxidative parameters, oxidative DNA damage, and urotensin-II in schizoaffective disorder patients
Kılıç, O. H. T., Aksoy, İ., Elboğa, G., & Bülbül, F. (2018) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2018.1468637 · Cited by 4 · see citing works
Genomic and Proteomic Mechanisms and Models in Toxicity and Safety Evaluation of Nutraceuticals
Kadakkuzha, B. M., Liu, X.-A., Swarnkar, S., & Chen, Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802147-7.00018-8 · Cited by 4 · see citing works
Clari, R., McNamara, R. K., & Szeszko, P. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-35206-6_19 · Cited by 3 · see citing works
Nutrition and Psychiatric Disorders: Focus on Schizophrenia
Mansour, H. M. (2022) · Nutritional neurosciences · doi:10.1007/978-981-19-5021-6_15 · Cited by 3 · see citing works
Montazer, M., Ebrahimpour‐Koujan, S., Surkan, P. J., & Azadbakht, L. (2022) · Advances in Nutrition · doi:10.1093/advances/nmac083 · Cited by 2 · see citing works
Perrotta, C., Carnovale, C., Pozzi, M., Palma, C. D., Cervia, D., Nobile, M., & Clementi, E. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100061 · Cited by 2 · see citing works
Pawełczyk, T., Pawełczyk, A. M., & Rabe‐Jabłońska, J. (2009) · Psychiatria i Psychologia Kliniczna · Cited by 2 · see citing works
Bahrambeigi, S., Khatamnezhad, M., Asri‐Rezaei, S., Dalir‐Naghadeh, B., Javadi, S., & Mirzakhani, N. (2021) · PubMed Central · doi:10.30466/vrf.2019.105811.2514 · Cited by 2 · see citing works
Gholipour, D., Shahraki, M., Saravani, M., Payandeh, A., & Eslahi, H. (2024) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2022.4292.1 · Cited by 2 · see citing works
Nonpharmalogical Substances for Early Intervention
Conus, P. (2016) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000440922 · Cited by 1 · see citing works
Esfandiari, M., Bagheri, H., Mirarab-Razi, V., Razi, S. M., & Rashidinejad, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-81404-5_24-1 · Cited by 1 · see citing works
Messer, T., Tiltscher, C., & Schmauß, M. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1849-8_2 · Cited by 1 · see citing works
Why Produce Food-Bioactive Compounds to Generate Functional Grade Foods?
Marsanasco, M., & Alonso, S. D. V. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96421 · Cited by 1 · see citing works
Kombinationen von Psychopharmaka
Messer, T., Tiltscher, C., & Schmauß, M. (2010) · Springer eBooks · doi:10.1007/978-3-211-85473-0_11 · Cited by 1 · see citing works
Long-Chain Omega-3 Fatty Acids and Psychotic Disorders
Mossaheb, N., Schloegelhofer, M., Schaefer, M. R., Fusar‐Poli, P., Smesny, S., McGorry, P. D., Berger, G. E., & Amminger, G. P. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-215-5_9
Yurt, K. K., Kıvrak, E. G., Altun, G., Aktaş, A., Kaplan, A. A., & Kaplan, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815238-6.00011-0
Schüßler, G., Kinzl, J. F., Knecht, T., & Baumgartner, S. (2010) · Springer eBooks · doi:10.1007/978-3-211-88900-8_19
Hooton, C. (1997) · Dialnet (Universidad de la Rioja)
Physiological Aberrations in Patients with Schizophrenia
Nilsson, B. M. (2009) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
(2009) · CRC Press eBooks · doi:10.3109/9780203092835-3
Current awareness: Pharmacoepidemiology and drug safety
(2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1486
Zhao, H., Han, X., Li, L., Zhang, X., Liao, Y., Zhang, H., Li, W., Shi, J., Lai, W., Wang, W., et al. (2022) · medRxiv · doi:10.1101/2022.05.11.22274935
Neuropsychiatric disorders and antioxidant vitamins E and C supplementation
Ghodake, S. R. (2024) · International Journal of Clinical Biochemistry and Research · doi:10.18231/j.ijcbr.2024.001
Nutritional Interventions vs. Pharmacological Interventions
Darwish, S. F., Mageed, S. S. A., Raouf, A. A., Elbadry, A. M. M., & Mahmoud, A. M. A. (2024) · Nutritional neurosciences · doi:10.1007/978-981-97-2681-3_20
Ghanem, Y., Almarshedi, A. A., Adam, M. A. A., Eid, M., Karaliūnienė, R., Philip, S., & Hayek, S. E. (2024) · Nutritional neurosciences · doi:10.1007/978-981-97-2681-3_12
Reactive oxygen species and psychiatric disorders
Knežević, N. N., Nenic, K., Knezevic, E., & Janković, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27333-9.00016-6
Goodness, A. T., Onaolapo, O. J., & Onaolapo, A. Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.06.697920
Tortajada, J. J., Bulduk, B. K., Alfonso-Landete, B., Barriga, P. A., Ballvé, B., Garrabou, G., Vilella, E., Alonso, Y., Valiente-Pallejà, A., & Martorell, L. (2026) · General Psychiatry · doi:10.1002/gps3.70023
- Authors
- Sivrioglu, E. Y., Kirli, S., Sipahioglu, D., Gursoy, B., & Sarandöl, E.
- Affiliations
- Bursa Uludağ Üni̇versi̇tesi̇ (TR)
- Corresponding author
- Sivrioglu, E.Y.
- ORCID
- Sarandöl, E.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-10
- Volume
- 31
- Issue
- 7
- Pages
- 1493-1499
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2040401967
- Cited by
- 102
- References
- 37
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 11 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 8 · 2016: 5 · 2015: 9 · 2014: 4 · 2013: 4 · 2012: 3
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Bursa Uludag University - AVESIS (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Biochemistry › Antioxidant Activity and Oxidative Stress
- Keywords
- schizophrenia, omega-3 fatty acids, vitamin E supplementation, vitamin C supplementation, haloperidol, antipsychotic adverse effects, akathisia, oxidative stress, antioxidant supplementation, superoxide dismutase, malondialdehyde, glutathione peroxidase, negative symptoms, positive symptoms
- MeSH terms
- Adolescent, Adult, Antioxidants, Ascorbic Acid, Erythrocytes, Female, Haloperidol, Humans, Male, Malondialdehyde, Middle Aged, Pilot Projects, Schizophrenia, Schizophrenic Psychology, Superoxide Dismutase, Antipsychotic Agents, Vitamin E, Lipid Peroxidation, Fatty Acids, Omega-3, Treatment Outcome, Akathisia, Drug-Induced
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review